| Name | Title | Contact Details |
|---|---|---|
Curtis Golston |
Director IT Operations | Profile |
Diamond Healthcare Corporation is the national leader in the planning, development and operation of high quality Behavioral Health Services in partnership with healthcare organizations. Diamond`s client relationships span a diverse geographic and demographic range — from rural critical access hospitals to urban academic medical centers, from sole community hospitals to multi-hospital health systems, including faith-based healthcare organizations, not-for-profit systems and for-profit hospital companies. Diamond offers a comprehensive range of healthcare services.
BioTek reMEDys is a specialty pharmacy that provides medications and support services to patients, physicians, nurses, payers, and pharma. They focus on specific disease states and provide expert care to ensure appropriate dosages and treatments. They ...
Physician Support Systems is a Mount Joy, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Components is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.